AmCad BioMed Corporation reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was TWD 17.35 million compared to TWD 19.97 million a year ago. Net loss was TWD 11.48 million compared to TWD 8.3 million a year ago. Basic loss per share from continuing operations was TWD 0.22 compared to TWD 0.16 a year ago.
For the six months, sales was TWD 34.58 million compared to TWD 31.69 million a year ago. Net loss was TWD 19.21 million compared to TWD 19.35 million a year ago. Basic loss per share from continuing operations was TWD 0.36 compared to TWD 0.36 a year ago.